Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Magic Show Featuring "Kuco" for Pain and Fear During Invasive Procedures

NCT07746973 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06-29
Last updated
2026-08-05

Condition(s) studied

Procedure-Related PainProcedure-Related FearPeripheral Intravenous CatheterizationVenipuncture

Investigational drug(s) / intervention(s)

Kuco Magic Show

Kuco Magic Show: Participants assigned to the intervention group will receive a standardized magic show featuring the "Kuco" puppet as a behavioral distraction technique before and throughout the invasive procedure (venipuncture or peripheral intravenous catheter insertion). The intervention will be delivered by a trained researcher using a standardized protocol that includes interactive magic tricks and verbal engagement to maintain the child's attention during the procedure. The magic show will begin approximately 2 minutes before the procedure and continue until the procedure is completed, in addition to routine clinical care.

Study summary

Children frequently experience pain and fear during invasive procedures such as venipuncture and peripheral intravenous catheter insertion. These experiences may negatively affect children's cooperation during procedures and increase anxiety related to future healthcare encounters. Non-pharmacological distraction techniques are recommended to reduce procedure-related pain and fear in pediatric patients.

This randomized controlled trial aims to evaluate the effect of a standardized magic show featuring "Kuco" on pain and fear experienced by children during invasive procedures. Eighty children aged 5-8 years who require venipuncture or peripheral intravenous catheter insertion will be randomly assigned to either an intervention group or a control group. Children in the intervention group will receive a standardized magic show performed with the "Kuco" puppet before and throughout the invasive procedure, whereas children in the control group will receive routine clinical care only.

Pain and fear will be assessed immediately before and after the procedure using the Wong-Baker FACES Pain Rating Scale and the Children's Fear Scale. The findings are expected to provide evidence regarding the effectiveness of a magic show-based distraction intervention for reducing procedure-related pain and fear in children.

Eligibility

Sex
ALL
Min age
5 Years
Max age
8 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Children aged 5 to 8 years. * Requiring venipuncture or peripheral intravenous catheter insertion in the pediatric emergency department, pediatric blood collection unit, or pediatric day-care unit. * Able to communicate in Turkish. * Conscious and able to respond to the study scales. * No visual or hearing impairment that would interfere with participation in the intervention or outcome assessment. * Parent or legal guardian provides written informed consent, and the child provides assent when appropriate. Exclusion Criteria: * Presence of a chronic psychiatric or neurological disorder. * Presence of a severe chronic medical condition that may affect pain or fear perception. * Administration of analgesic, sedative, or anxiolytic medication before the procedure. * Previous participation in this study. * Child or parent refuses to participate or withdraws consent at any stage of the study. * Failure to complete the invasive procedure or the study assessments.

Primary outcome measure(s)

  • Procedure-Related Pain — Immediately before and within 1 minute after the invasive procedure.
    Pain intensity will be assessed using the Wong-Baker FACES Pain Rating Scale immediately before and within 1 minute after the invasive procedure. The scale ranges from 0 to 10, with higher scores indicating greater pain intensity.
  • Procedure-Related Fear — Immediately before and within 1 minute after the invasive procedure.
    Fear will be assessed using the Children's Fear Scale immediately before and within 1 minute after the invasive procedure. The scale ranges from 0 to 4, with higher scores indicating greater fear.

Trial sites (1)

FacilityCityRegionStatus
Bingöl State Hospital Bingoel Bingöl
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07746973 on ClinicalTrials.gov ↗ ← All trials in Turkey